Long-term follow-up of therapeutic efficacy of everolimus-eluting bioresorbable vascular scaffold in comparison to everolimus-eluting stent in treatment of chronic total occlusion guided by intracoronary imaging

The Egyptian Heart Journal

Table 1 Demographic data

History (risk factors)		EES group	BVS group	Test	p value	Sig.
History (risk factors)		No. = 40	No. = 20	Test	p value	Sig.
Age	Mean ± SD	57.38 ± 6.98	56.15 ± 9.25	0.574^b	0.568	NS
Age	Range	45–75	34–80	0.574^b	0.568	NS
Sex	Male	37 (92.5 %)	19 (95%)	0.463^b	0.457	NS
Sex	Female	5 (12.5 %)	1 (5%)	0.463^b	0.457	NS
DM	Negative	19 (47.5%)	8 (40.0%)	0.881^a	0.459	NS
DM	Positive	21 (52.5)	12 (60.0%)	0.881^a	0.459	NS
Hyperlipidemia	Negative	5 (12.5%)	0 (0.0%)	2.727^a	0.099	NS
Hyperlipidemia	Positive	35 (87.5%)	20 (100.0%)	2.727^a	0.099	NS
HTN	Negative	17 (42.5%)	6 (30.0%)	0.881^a	0.348	NS
HTN	Positive	23 (57.5%)	14 (70.0%)	0.881^a	0.348	NS
History of MI	Negative	24 (60.0%)	14 (70.0%)	0.574^a	0.449	NS
History of MI	Positive	16 (40.0%)	6 (30.0%)	0.574^a	0.449	NS
Family history of premature CAD	Negative	31 (77.5%)	17 (85.0%)	0.469^a	0.494	NS
Family history of premature CAD	Positive	9 (22.5%)	3 (15.0%)	0.469^a	0.494	NS
Previous PCI, CABG	Negative	27 (67.5%)	17 (85.0%)	2.088^a	0.148	NS
Previous PCI, CABG	Positive	13 (32.5%)	3 (15.0%)	2.088^a	0.148	NS

NS non-significant, S significant, HTN hypertension, MI myocardial infraction, CAD coronary artery disease, PCI percutaneous coronary intervention, CABG coronary artery bypass graft
^aChi-square test
^bIndependent t test